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To the Editor

The complement system is pivotal in protection against pathogens, but it also plays important roles in bridging innate and adaptive immune responses ([@bib11]) and in modulating local and systemic inflammation ([@bib5]). Activation of complement occurs through three different pathways (classical, alternative, and lectin), converges at C3 cleavage, and culminates in the formation of the membrane attack complex. The anaphylatoxic fragments, C3a and C5a, generated during the proteolytic cascade, recruit immune cells that can promote the removal of debris and pathogens, but they can also cause tissue damage ([@bib5]).

The main source of complement is the liver. However, locally produced complement, particularly C3, can modulate inflammation in a variety of organs. There is also evidence that complement components are produced not only by immune cells such as macrophages and dendritic cells but also by nonimmune cells, which can contribute to local complement synthesis. In the skin, keratinocytes are a potential source of C3 ([@bib7]). A role for C3 in the skin has been identified in UV-induced immune tolerance ([@bib3]) and in the protection against T-cell--mediated inflammation ([@bib8]). Furthermore, locally produced C3 contributes to the inflammatory responses accompanying wound healing ([@bib9]), an effect mediated mainly through C5a/C5aR interactions. The latter also play an important role in influencing the skin microbiome ([@bib1]). In keeping with these observations in animal models, complement has been shown to have a role in the pathogenesis of many human skin diseases, including psoriasis ([@bib4]).

Psoriasis is an inflammatory skin disease characterized by epidermal hyperplasia, infiltration of immune cells, and secretion of inflammatory cytokines ([@bib13]). The anaphylatoxic fragments, C3a and C5a, have been found in corneal scale extracts from psoriatic lesions ([@bib12]). The C5a from these lesions has been shown to chemoattract monocyte-derived dendritic cells ([@bib6]), indicating that complement may contribute to the inflammatory process in this disease. In the inducible AP-1--dependent psoriasis-like mouse model, the S100A8-S100A9 complex that promotes skin inflammation has been shown to up-regulate C3 expression ([@bib10]). Psoriasis-like dermatitis can be induced by topical application of the toll-like receptor 7 agonist imiquimod (IMQ) ([@bib14]) in the form of Aldara cream (3M Pharmaceuticals, St Paul, MN) ([@bib15]). Here, we explore the role of complement in IMQ-mediated psoriasiform dermatitis.

We first tested whether cutaneous IMQ treatment induces local C3 synthesis (experimental methods are provided as [Supplementary Materials](#appsec1){ref-type="sec"} online) and found a progressive increase in C3 mRNA in the skin with repeated IMQ applications ([Figure 1](#fig1){ref-type="fig"}a, and see [Supplementary Figure S1](#appsec1){ref-type="sec"}a online). Immunohistochemistry showed that the C3 expression was predominantly in the dermis (see [Supplementary Figure S1](#appsec1){ref-type="sec"}b). In vitro experiments with isolated dermal stromal cells showed that these cells can produce C3 upon stimulation with inflammatory cytokines known to be induced in IMQ-treated skin but not upon direct challenge with a toll-like receptor 7 agonist (see [Supplementary Figure S1](#appsec1){ref-type="sec"}c). To test whether C3 contributes to the psoriatic-like lesions induced by IMQ, we then treated wild-type (WT) and *C3*^*--/--*^ mice for 7 consecutive days. The treatment resulted in skin thickening, scaling, and erythema ([Figure 1](#fig1){ref-type="fig"}b). However, mice lacking C3 displayed less skin inflammation compared with WT mice ([Figure 1](#fig1){ref-type="fig"}c). Consistent with the reduced skin response in *C3*^*--/--*^ mice, we found significantly fewer infiltrating neutrophils, but slightly more monocytes, and no difference in the number of resident γδ T cells compared with WT animals ([Figure 1](#fig1){ref-type="fig"}d). IL-17 secretion by γδ T cells plays a key role in the IMQ-induced psoriasis model ([@bib14]), and our data confirmed that IL-17 secretion was mainly restricted to these cells. The frequency of IL-17--positive γδ T cells in both skin and draining lymph nodes was significantly lower in the absence of C3 ([Figure 1](#fig1){ref-type="fig"}e and f). All animals were handled in accordance with institutional guidelines, and the UK Home Office approved the procedures.

We next evaluated whether C3 contributes to the local inflammatory response. To this end, we analyzed the gene expression of a selected number of cytokines/chemokines known to be induced in the skin by IMQ treatment ([@bib2], [@bib15]). At the peak of clinical inflammation on day 7, the *C3*^*--/--*^ mice did not show any obvious differences in inflammatory gene expression ([Figure 2](#fig2){ref-type="fig"}a). However, at the onset of the clinical pathology, day 3, when the cytokine/chemokine gene response peaks ([@bib2]), C3-deficient mice had a markedly reduced response, suggesting that C3 modulates the inflammatory gene induction that precedes clinical manifestations. To substantiate this, we carried out a time-course analysis of skin gene expression after 3 days of IMQ treatment. This showed that in the absence of C3, the resolution of the IMQ-triggered inflammation was faster compared with WT mice. Twenty-four hours after the last application, C3-deficient mice had significantly reduced levels of all genes analyzed, namely those for IL-1α, TNF-α, IL-17a, IL-23a, CXCL1, and CCL2 (see [Supplementary Figure S2](#appsec1){ref-type="sec"}a and [Supplementary Table S1](#appsec1){ref-type="sec"} online). Consistent with this, thickening of the skin assessed by histology was significantly reduced in the *C3*^*--/--*^ mice ([Figure 2](#fig2){ref-type="fig"}b and c). The altered skin pathology in the IMQ-treated C3-deficient mice appeared to affect mainly the epidermis. Untreated skin of WT and *C3*^*--/--*^ mice was histologically indistinguishable.

In summary, we demonstrate that C3 is involved in the development and resolution of the psoriasiform skin inflammation induced by short-term treatment with IMQ. The proinflammatory effect of C3 is likely to be mediated by several mechanisms. In the absence of C3 the expression of psoriasis-relevant genes in the skin was impaired, neutrophil infiltration into the inflamed site was decreased, and IL-17 production by γδ T cells in the skin and the draining lymph nodes was reduced. Taken together, these data support a proinflammatory role of C3 during psoriasis-like skin inflammation.
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![**IMQ-induced skin inflammation and psoriasiform dermatitis is impaired in C3-deficient mice.** IMQ was applied for 7 days to the ear of BALB/c WT (black square) and BALB/c.*C3*^--/--^ (red circle) mice. (**a**) C3 expression in whole skin quantified by quantitative real-time --PCR 24 hours after the last application (n = 4). Naïve indicates untreated mice, mean ± standard error of the mean relative to cyclophilin, unpaired *t* test. (**b**) Representative pictures of IMQ-treated ears at day 7. (**c**) Ear thickness (mean ± standard error of the mean) and clinical scores (mean ± standard deviation) for erythema and scaling. Representative experiment of two, Mann-Whitney test. (**d**) Number of CD45^+^ cells, neutrophils (Ly-6G^+^), monocytes (CD11b^+^Ly-6C^+^Ly-6G^--^), and γδ T cells (CD4^--^CD3^+^γδTCR^+^) at day 7. (**e--f**) Proportion of IL-17^+^ γδ T cells from (**e**) skin and (**f**) LN after in vitro restimulation. Mean ± standard error of the mean, unpaired *t* test. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, ^∗∗∗^*P* \< 0.001, ^∗∗∗∗^*P* \< 0.0001. d, day; IMQ, imiquimod; LN, lymph node; M, meter; no., number; WT, wild type.](gr1){#fig1}

![**Reduced early proinflammatory response and skin thickening in IMQ-treated C3-deficient mice.** (**a**) IMQ was applied for 3 or 7 days to the ear of BALB/c WT (black square) and BALB/c.*C3*^--/--^ (red circle) mice. Gene expression was analyzed in whole skin 24 hours after the last IMQ exposure (n = 3--5/group). Naïve indicates untreated mice, mean ± standard error of the mean relative to the control gene cyclophilin (SYBR Green assay, Life Technologies, Waltham, MA) or GADPH (Taqman assay ThermoFisher, Waltham, MA) levels. (**b**) Representative images showing hematoxylin and eosin staining of cross-sectional ear skin from BALB/c and BALB/c*.C3*^--/--^ mice untreated and 48 hours after the third IMQ application. The epidermis/dermis boundaries are indicated. Scale bars = 50 μm. (**c**) Quantification of whole-skin and epidermal thickness calculated using Image J software (National Institutes of Health, Bethesda, MD). Each symbol represents an individual mouse (n = 4). Mean ± standard error of the mean; unpaired *t* test. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01. d, day; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IMQ, imiquimod; M, meter; ns, not significant; TNF, tumor necrosis factor; WT, wild type.](gr2){#fig2}
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